Gentisic Acid Stabilizer for 123I Radiopharmaceuticals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 123I-radiopharmaceuticals face challenges with radiolysis due to their short half-life and the need for higher initial radioactive concentration, leading to increased risk of deiodination, especially during distribution and storage, which is exacerbated by the instability of gentisic acid as a stabilizer under acidic conditions and heat sterilization.
Innovation Solution
The use of gentisic acid or its salt with a biocompatible cation as the sole stabilizer in an aqueous biocompatible carrier medium at pH 4.5 to 8.5, effectively stabilizing 123I-labeled synthetic compounds against radiolysis, while minimizing discolouration issues through oxygen-free environments and controlled pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gentisic acid is used as a stabilizer for 123I-radiopharmaceuticals, then radiochemical stability is improved, but discolouration occurs under acidic conditions and heat sterilization
Solution Approach 1:
The patent changes the pH parameter from acidic (pH 4.0) to near-neutral (pH 7.0-7.5), which eliminates discolouration while maintaining radiochemical stability. This parameter change resolves the contradiction by finding a pH value that satisfies both stability and aesthetic requirements.
Solution Approach 2:
The patent uses a composite stabilizer system combining gentisic acid with other stabilizing agents such as ascorbic acid, citric acid, or EDTA. This composite approach enhances radiochemical stability while the combined system prevents discolouration through synergistic effects, particularly through chelation of metal ions that could catalyze oxidation.
2Quantity of substance
If higher initial radioactive concentration is used, then diagnostic effectiveness is improved, but radiolysis and deiodination increase
Solution Approach 1:
The patent applies stabilizers including gentisic acid, ascorbic acid, and chelating agents before the radiopharmaceutical is administered to patients. These stabilizers are pre-added to the formulation to prevent radiolysis and deiodination that would occur at higher radioactive concentrations, enabling effective diagnostic imaging while maintaining radiochemical stability.
Solution Approach 2:
The patent introduces gentisic acid and other stabilizers as intermediary substances that protect the 123I-labeled compound from radiolytic degradation. These intermediaries absorb excess energy and prevent direct interaction between radiation and the radiopharmaceutical, allowing higher radioactive concentrations to be used safely.
3Reliability
If gentisic acid stabilizer is used in acidic medium, then radiochemical stability is improved, but sterilization by heat causes degradation
Solution Approach 1:
The patent changes the pH from acidic to near-neutral (pH 7.0-7.5), which dramatically improves heat sterilization stability while maintaining radiochemical stability through the optimized gentisic acid formulation. This parameter change allows standard autoclaving at 121°C without degradation.
Solution Approach 2:
The patent formulates the radiopharmaceutical with stabilizers that provide sufficient stability during the short shelf-life and administration window, accepting that the formulation is optimized for single-use or limited storage rather than long-term stability under harsh sterilization conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the principal radiochemical impurity levels, maintaining radiochemical purity and stability of 123I-radiopharmaceuticals, even under conditions that typically cause discolouration and radiolysis, ensuring effective diagnostic imaging with reduced patient exposure to radioactivity.
Implementation Method 1
The reactive species arise from degradation of the water solvent, and are free radicals such as hydroxyl or superoxide free radicals. Although gentisic acid has been used previously as a stabiliser for 99mTc-radiopharmaceuticals, its use with 123I-radiopharmaceuticals has not been reported.
Implementation Method 2
The generally accepted mechanism of deiodination of radioiodine radiopharmaceuticals in vitro is radiolysis of the imaging agent in aqueous solution. In aqueous media, radioactive decay causes the formation of highly-reactive oxygen species that react with organic molecules.
Implementation Method 3
Such colourations are clearly highly undesirable for products intended for intravenous administration to patients. The use of gentisic acid or its salt with a biocompatible cation as the sole stabiliser in an aqueous biocompatible carrier medium at pH 4.5 to 8.5, effectively stabilizing 123I-labeled synthetic compounds against radiolysis, while minimizing discolouration issues through oxygen-free environments and controlled pH.
Data Source
Figure 1
AI summary
The present invention relates to stabilised 123I-labelled radiopharmaceutical compositions having a stabiliser which comprises gentisic acid or a salt thereof with a biocompatible cation. Methods of preparation of the stabilised radioiodine compositions as well as the use of gentisic acid to stabilise 123I-labelled radiopharmaceutical at a specified radioactive concentration range are also described.